Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Ankylosing Spondylitis Patients Have Impaired Osteoclast Gene Expression in Circulating Osteoclast Precursors.

Perpétuo IP, Caetano-Lopes J, Vieira-Sousa E, Campanilho-Marques R, Ponte C, Canhão H, Ainola M, Fonseca JE.

Front Med (Lausanne). 2017 Jan 27;4:5. doi: 10.3389/fmed.2017.00005. eCollection 2017. Erratum in: Front Med (Lausanne). 2017 Apr 12;4:38.

2.

Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Ankylosing Spondylitis.

Perpétuo IP, Raposeiro R, Caetano-Lopes J, Vieira-Sousa E, Campanilho-Marques R, Ponte C, Canhão H, Ainola M, Fonseca JE.

PLoS One. 2015 Dec 16;10(12):e0144655. doi: 10.1371/journal.pone.0144655. eCollection 2015.

3.

TNF Induction of NF-κB RelB Enhances RANKL-Induced Osteoclastogenesis by Promoting Inflammatory Macrophage Differentiation but also Limits It through Suppression of NFATc1 Expression.

Zhao Z, Hou X, Yin X, Li Y, Duan R, Boyce BF, Yao Z.

PLoS One. 2015 Aug 19;10(8):e0135728. doi: 10.1371/journal.pone.0135728. eCollection 2015.

4.

Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor-κβ expression in monocytes from patients with early rheumatoid arthritis.

Perpétuo IP, Caetano-Lopes J, Rodrigues AM, Campanilho-Marques R, Ponte C, Canhão H, Ainola M, Fonseca JE.

RMD Open. 2017 Jul 13;3(1):e000365. doi: 10.1136/rmdopen-2016-000365. eCollection 2017.

5.
6.

Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.

Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP.

J Bone Miner Res. 2005 Sep;20(9):1659-68. Epub 2005 May 2.

7.
8.

Defective osteoclastogenesis by IKKbeta-null precursors is a result of receptor activator of NF-kappaB ligand (RANKL)-induced JNK-dependent apoptosis and impaired differentiation.

Otero JE, Dai S, Foglia D, Alhawagri M, Vacher J, Pasparakis M, Abu-Amer Y.

J Biol Chem. 2008 Sep 5;283(36):24546-53. doi: 10.1074/jbc.M800434200. Epub 2008 Jun 19.

10.

Bone impairment in phenylketonuria is characterized by circulating osteoclast precursors and activated T cell increase.

Roato I, Porta F, Mussa A, D'Amico L, Fiore L, Garelli D, Spada M, Ferracini R.

PLoS One. 2010 Nov 30;5(11):e14167. doi: 10.1371/journal.pone.0014167.

11.

Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis.

Perpétuo IP, Caetano-Lopes J, Rodrigues AM, Campanilho-Marques R, Ponte C, Canhão H, Ainola M, Fonseca JE.

Biomed Res Int. 2017;2017:2690402. doi: 10.1155/2017/2690402. Epub 2017 Feb 13.

12.

CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.

Kim JY, Min JY, Baek JM, Ahn SJ, Jun HY, Yoon KH, Choi MK, Lee MS, Oh J.

Bone. 2015 Oct;79:242-51. doi: 10.1016/j.bone.2015.06.011. Epub 2015 Jun 21.

PMID:
26103094
13.

Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling.

Kalliolias GD, Zhao B, Triantafyllopoulou A, Park-Min KH, Ivashkiv LB.

Arthritis Rheum. 2010 Feb;62(2):402-13. doi: 10.1002/art.27200.

14.

Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin imbalance.

Faienza MF, Brunetti G, Colucci S, Piacente L, Ciccarelli M, Giordani L, Del Vecchio GC, D'Amore M, Albanese L, Cavallo L, Grano M.

J Clin Endocrinol Metab. 2009 Jul;94(7):2269-76. doi: 10.1210/jc.2008-2446. Epub 2009 Apr 28.

PMID:
19401376
15.

Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.

Kamel Mohamed SG, Sugiyama E, Shinoda K, Hounoki H, Taki H, Maruyama M, Miyahara T, Kobayashi M.

Biochem Biophys Res Commun. 2005 Apr 15;329(3):839-45.

PMID:
15752732
16.

Role of IGF-I signaling in regulating osteoclastogenesis.

Wang Y, Nishida S, Elalieh HZ, Long RK, Halloran BP, Bikle DD.

J Bone Miner Res. 2006 Sep;21(9):1350-8.

17.

Corrigendum: Ankylosing Spondylitis Patients Have Impaired Osteoclast Gene Expression in Circulating Osteoclast Precursors.

Perpétuo IP, Caetano-Lopes J, Vieira-Sousa E, Campanilho-Marques R, Ponte C, Khmelinskii N, Canhão H, Ainola M, Fonseca JE.

Front Med (Lausanne). 2017 Apr 12;4:38. doi: 10.3389/fmed.2017.00038. eCollection 2017.

18.

Monocytes from patients with osteoarthritis display increased osteoclastogenesis and bone resorption: the In Vitro Osteoclast Differentiation in Arthritis study.

Durand M, Komarova SV, Bhargava A, Trebec-Reynolds DP, Li K, Fiorino C, Maria O, Nabavi N, Manolson MF, Harrison RE, Dixon SJ, Sims SM, Mizianty MJ, Kurgan L, Haroun S, Boire G, de Fatima Lucena-Fernandes M, de Brum-Fernandes AJ.

Arthritis Rheum. 2013 Jan;65(1):148-58. doi: 10.1002/art.37722.

19.

Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.

Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.

Biochem Pharmacol. 2013 Sep 15;86(6):782-90. doi: 10.1016/j.bcp.2013.07.015. Epub 2013 Aug 6.

PMID:
23928189
20.

TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis.

Abu-Amer Y, Abbas S, Hirayama T.

J Cell Biochem. 2004 Nov 15;93(5):980-9.

PMID:
15389885

Supplemental Content

Support Center